Introduction
Ischemic stroke (IS) is a major cause of death and disability in many countries. Several environmental factors, such as hypertension, diabetes, atrial fibrillation, smoking and chronic kidney disease have been identified as risk factors for IS [1, 2] . However, these factors only account for a proportion of stroke risk. Studies showed that nearly one-half of stroke risk can be attributed to genetic risk factors [3, 4] . To date, several candidate genes have been shown to influence the stroke risk in different populations [5] [6] [7] [8] . Recently, increasing evidence shows that inflammation plays an important role in the occurrence and progression of acute ischemic stroke [9] [10] [11] [12] ; thus, the roles of genetic variants of the inflammation related gene attract much interest.
The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and a receptor for advanced glycation end products (AGEs) [13, 14] . AGE-RAGE interaction alters several cell functions through modulation of multiple intracellular signaling pathways [15] . The RAGE is expressed in various cell types including neurons. In brain, RAGE is present on neurons, glia, and endothelial cells [16] . The RAGE has been demonstrated to play a central role in the pathogenic mechanisms of a growing number of neurological diseases, e.g. Alzheimer's disease (AD) and stroke [17] [18] [19] . The role of RAGE in the pathophysiology of acute ischemia was directly documented by using genetic RAGE deficiency animal model of cerebral ischemia [20] . RAGE contribute to delayed neuronal death after global cerebral ischemia by enhancing vascular injury and deleterious glia-mediated inflammation [21] . The plasma levels of soluble RAGE (sRAGE) is reported to be a biomarker for the risk and severity of acute ischemic stroke, especially in those without a source of cardio-embolism [22] . Circulating sRAGE reflects vascular inflammation status [21, 23] . Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia, indicating that RAGE signaling directly contributes to pathology in cerebral ischemia [18] .
RAGE is encoded by chromosome 6 at the major histocompatibility locus (MHC) class II/III junction. To date, more than 20 several single nucleotide polymorphisms (SNP) in the RAGE gene have been identified [24] , amongst which, -429T>C (rs1800625), -374T>A (rs1800624), G82S (g.555G>A, rs2070600) were mostly studied. The role of the polymorphisms of RAGE gene in several disease conditions, e.g., coronary artery disease (CAD), heart failure, nephropathy, chronic renal insufficiency with diabetes have been previously documented [25] [26] [27] [28] [29] .
Considering the role of RAGE in inflammation and the pathophysiology of ischemic stroke, we postulate there might be a possible association between the polymorphisms of RAGE gene and stroke. In the present study, we enrolled patients with ischemic stroke from a Chinese population to explore the role of RAGE gene polymorphisms in determining the susceptibility of ischemic stroke.
Materials and Methods
A total of 384 patients were included in this study from August 2006 to July 2009. All the patients were diagnosed as having first ever IS by at least two independent neurologists. The diagnosis of IS were confirmed based on strict neurological examination, computed tomography or magnetic resonance imaging, according to the criteria of Trial of ORG 10172 in Acute Stroke Treatment (TOAST) [30] . According to these criteria, we enrolled only patients with subtype of small vessel disease (SVD) and large vessel disease (LVD). Patients with the subtypes, such as cardio-embolism, stoke of other determined etiology and stroke of undetermined etiology were not included in this study. The other exclusive criteria included: recurrent IS, cerebrovascular malformations, brain tumors and traumatic cerebrovascular diseases, cardiovascular diseases, peripheral vascular diseases, atrial fibrillation, infections and malignant disorders. A total of 425 unrelated age and sex matched healthy volunteers were included in this study as controls. All these controls were enrolled among participants examined through annual health check-up program. Controls with stroke history, neurological diseases, ischemic heart diseases or any chronic diseases were excluded. All the participants were ethnically Chinese Han and all were from southeast China area. Main clinical data including age, sex, body mass index, smoking history, arterial hypertension, diabetes mellitus (DM), and family history of stroke were recorded. Fasting blood samples were collected from patients and controls. Body mass index was calculated as the weight divided by height squared (BMI, kg/m2). Hypertension referred to as have a previous diagnosis of hypertension by a Physician, and use a prescription antihypertensive medication and/or have a systolic BP ≥145 mm Hg and/or a mean diastolic BP ≥95 mm Hg during interview. The smoker category included current smokers who smoke daily. Non consumers of tobacco were defined as persons who had never smoked or had consumed less than 20 packs of cigarettes or 360g of tobacco in their lifetime or less than one cigarette per day [31] . Total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), glucose levels and high sensitivity-C reactive protein (hs-CRP) were determined. The study was approved by the ethics committee of our hospital and informed consent was obtained from all participants.
Detection of serum inflammatory factors
Blood samples were taken immediately when the diagnosis was established in 150 patients with newly diagnosed first ever acute ischemic stroke. sRAGE levels in sera were determined by RAGE Immunoassay (R&D Systems, Minneapolis, MN, USA) in an ELISA format, with wells coated with murine anti-human RAGE mAb in which serum samples (50 μl/well, normally 1:2 v/v dilution) were incubated. A polyclonal capture antibody against the extracellular domain of RAGE was used for detection. The minimum detectable sRAGE concentration is 4.12 pg/ml, according to the manufacturer and the inter-assay coefficient of variation is < 8%. Other cytokines [included serum intetleukin-6 (IL-6), high sensitivity-C reaction protein (hs-CRP) and plasminogen activator inhibitor-1 (PAI-1)] were measured using a Luminex IS 100 instrument (Bio-Rad, Hercules, CA.). The coefficient of variation for controls ranged from 9 to 19% on the exponential phase of the standard curve.
Genotyping
Genotyping was performed by polymerase chain reaction-restriction fragment length polymor phism (PCR-RFLP) using AluI (Invitrogen) and Tsp509I (New England Biolabs) for 82G>S, -429T>C and -374T>A variations respectively, as described by Hudson et al. and Gu et al. [32, 33] . RFLPs were resolved using 10% polyacrylamide gel electrophoresis, stained with ethidium bromide and registered with a UVP BioChemi system.
Statistical Analysis
Continuous variables were tested for normality (Kolmogorov-Smirnov test). Variables with normal distribution describe as mean ± standard deviation. Variables without normal distribution, e.g., HDL-C, LDL-C, TC and TG were expressed as median (interquartile range = 25%-75% interquartile). Data on qualitative characteristics were expressed as percent values or absolute numbers, as indicated. Differences in demographic characteristics and vascular risk factors between patients and controls were compared by using Student's t test or ANOVA for continuous variables and the χ2 test for all categorical variables. Tests for Hardy-Weinberg equilibrium were conducted using χ2 tests. Genotypes and allele frequencies were compared by χ2 analysis or Fisher's exact test. Multivariate logistic regression analysis was used to determine the influence of RAGE polymorphisms on stroke risk, controlling potential confounding risk variables including age, sex, and other conventional risk factors. A forward stepwise (Likelihood Ratio) procedure was used for multivariable analysis. The associations between the RAGE haplotypes and IS risk were analyzed. The D´ value for the studied 4 SNPs were calculated with the SHEsis software [34] . Data were analyzed with the SAS 9.3 package (SAS Inc.NC, USA) and results were considered statistically significant at p< 0.05 using a 2-tailed test.
Results
Demographic data and risk factor profiles of patients and controls are presented in Table 1 . There were no significant differences between stroke and controls with regards to gender, BMI, TC, TG levels and smoking. However, hypertension and diabetes were more prevalent in ischemic stroke subjects than controls (p<0.001 and p=0.011, respectively). In addition, the LDL-C levels were higher in stroke subjects than in controls (p=0.007). Compared with controls, the stroke subjects had a significantly higher hs-CRP (7. Table 2 describes the genotype distributions and allele frequencies of RAGE polymorphisms in stroke and control subjects. The genotype frequencies for all polymorphisms did not differ significantly from those expected under Hardy-Weinberg equilibrium (all p>0.05). Generally, there were no significant differences of genotype distributions and alleles frequencies of -429T/C and -374 T/A between stroke subjects and control subjects (all p>0.05, Table 2 ). However, genotype and allele frequencies at 82G/S locus were significantly different between stroke subjects and control subjects. The presence of 82S/S genotype and 82S allele were significantly higher in stroke subjects than in controls (both p<0.001). We further performed multivariate logistic regression analysis to determine whether the 82S/S genotype or 82S allele was independent risk factors for stroke. The presence of ischemic stroke was considered as the outcome variable and the following variables were used as covariates: age, sex, TG, TC (HDL-C and LDL-C), hypertension, smoking, BMI, hs-CRP levels and DM. With the 82G/G genotype as reference, the presence of 82S/S homozygotes had a significantly increased risk for stroke (OR: 2.297; 95% CI: 1.583---3.333, p<0.001, Table 2 ) after adjustment with the above mentioned clinical variables. The 82S allele carriage presented a higher risk factor (adjusted OR=1.610, 95%CI: 1.322-1.960, p<0.001). The polymorphisms at -429T/C and -374 T/A of RAGE gene did not influence the susceptibility of stroke in this study.
The associations between the RAGE haplotypes and stroke risk were analyzed in this study. The D´ value and r 2 for the studied 3 SNPs were calculated with the SHEsis software [35] . All 3 SNPS were in strong LD (all D´>0.8). The estimated haplotype frequencies of the RAGE SNPs are shown in Table 3 . The haplotype of C -429 S 82 T -374 and T -429 S 82 A -374 were HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; T2DM, Type 2 diabetes mellitus; BMI, body mass index; hs-CRP, high sensitivity-C reactive protein; PAI-1, plasminogen activator inhibitor-1; IL-6, interleukin-6; sRAGE, soluble RAGE significantly more frequent in stroke subjects than controls (16.1% vs 9.4% and 6.1% vs 3.2%, respectively), while the C -429 G 82 T -374 was much lower in stroke subjects than controls (7.1% vs 11.9%, Table 3 ). Our data showed haplotype of C -429 S 82 T -374 and T -429 S 82 A -374 had significantly higher risks to develop IS (OR=1.864 and 1.931, respectively, all p<0.01). In contrast, the C -429 G 82 T -374 showed a protective for IS susceptibility (OR=0.568, p=0.001). Table 2 . Genotype and allele frequencies of RAGE polymorphism in the studied groups. Values were in number (N) and percentage (%), χ2, chi-square test; 95%CI, 95% confidence interval; adjusted OR, adjusted odds ratio. All groups were in Hardy-Weinberg equilibrium We further stratified the patients, according to stroke type, into small vessel disease (SVD) and large vessel disease (LVD) groups. The stroke subtypes were classified using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) [30] . We found that the genotype distributions and alleles frequencies of 82G/S were significantly different in both SVD and LVD subgroups (all p<0.001, Table 4 ). The presence of 82S was significantly higher in both SVD and LVD than in controls (both P<0.001, Table 4 ).
We further analyzed the serum cytokines levels in the stroke and control subjects according to the 82G/S genotype distributions. The 82S/S carriers had a lower sRAGE levels (611.58±131.32 vs 789.39±158.67, pg/mL, p=0.015), however, had a markedly higher CRP (9.346±1.36 vs.7.302±1.12 and 7.307±1.10, mg/L, p=0.032 and 0.035, respectively), IL-6 (26.32±3.45 vs 22.64±3.501 and 21.55±4.9, pg/mL, p=0.025 and 0.019, respectively) and PAI-1 levels (19.4±2.33 vs.17.44±2.67 and 14.45±3.98, ng/mL, p=0.046 and 0.012, respectively), compared with 82G/S and 82G/G carriers ( Fig.1 A-D) .
Discussion
In the present study, we studied the possible association between the RAGE gene polymorphisms and IS in a Chinese cohort. Of the three loci studied, we found that only the polymorphisms at 82G/S were associated with the risk for IS. The 82S/S homozygote carriers had a significantly increased risk for ischemic stroke (adjusted OR: 2.297; p<0.001). The haplotype analyses showed that the C -429 S 82 T -374 and T -429 S 82 A -374 had higher risk to develop IS (OR=1.864 and 1.931, respectively, all p<0.01), while the C -429 G 82 T -374 showed a protective for IS susceptibility (OR=0.568, p=0.001). Notably, we found that the 82S/S homozygote carriers had a higher inflammatory status compared with G/S and G/G genotypes, indicated by lower sRAGE level, higher IL-6, hs-CRP and PAI-1 levels. The polymorphisms at -374 and -429 loci did not influence the stroke risk and the above mentioned inflammation cytokines. Our findings in this study suggest that the 82G/S may be used as a genetic marker for the prediction of stroke occurrence in high risk subjects.
The 82G/S (82Gly→Ser) functional polymorphisms in the RAGE gene was one of the first identified polymorphisms of the RAGE gene and occurs in the ligand-binding V-domain of RAGE and therefore has attracted considerable interest [36] . The 82S allele enhances the ligand-binding affinity and increased the ligand-stimulated generation of inflammatory mediators in transfected cells and human monocytes compared to the common RAGE 82Gly allele. Recent observations indicated that the Gly82Ser polymorphism was associated with various diseases, including skin complications in type 2 diabetes, diabetic advanced nephropathy, coronary artery disease, and rheumatoid arthritis [36] [37] [38] .
Recently, RAGE is view as a novel biological and genetic marker for vascular disease. The association between the 82G/S polymorphism and cardiovascular disease is quite inconsistent. Jang et al. have reported that subjects with the SS homozygous mutation of the G82S polymorphism had increased risk factors for cardiovascular disease compared with those bearing at least one G allele in non-diabetic and non-obese Koreans [39] . G82S polymorphism in the RAGE gene is associated with diabetic retinopathy in Chinese population [40] , but no positive association between the polymorphisms at 82G/S and the presence and severity of CAD [41] . The association of the G82S polymorphism of RAGE with diabetic retinopathy was confirmed in the population of southern India [42] . However, in the Framingham offspring study, the 82S did not demonstrate positive association with the incidence of cardiovascular disease in diabetic or non-diabetic subjects [43] . A meta-analysis revealed no association between the RAGE −429T/C, −374T/A and G82S polymorphisms and coronary heart disease (CHD) risk [44] . A very recent showed that only one polymorphism of RAGE gene at rs1035798 (T>C), rather than the three loci in our study, had a significant association with the stroke subtype, but not with overall IS in Caucasian population. Several reasons may possibly account for the discrepancy between this study and ours: 1. Ethnic differences: Several studies reported that the genotype distribution of RAGE gene was quite variable among ethnic populations, especially between Caucasian and Chinese [45] [46] [47] [48] . 2. Enrollment: We enrolled only patients with first-ever IS, no recurrent IS were included in our study. However, more likely, the association of RAGE gene polymorphism and cardiovascular diseases and vasculopathy is ethnic and disease specific. Thus, multi-center study with larger samples is warranted to better address the role of RAGE polymorphism in vascular disease development.
Recently, inflammation has received increasing attention as a cause of atherosclerosis, coronary artery disease, and stroke. Several inflammatory biomarkers, including CRP, IL-6 and PAI-1 have been identified as predictors of the risk for stroke [49] [50] [51] [52] [53] . Recent studies reported the RAGE G82S polymorphism results in the enhancement of pro-inflammatory mechanisms in immune/ inflammatory diseases and vascular injury. There was a remarkable association of the G82S variant with elevated serum CRP levels, implying that the prevalence of RAGE 82S allelic variation may influence susceptibility to vascular disorders by affecting vascular inflammation [41] . Soluble RAGE (sRAGE) is inversely associated with chronic inflammatory state, diabetes, atherosclerosis and metabolic syndrome and may neutralize the AGEs-mediated damage by acting as a decoy [54] . The RAGE 82S allele up-regulates the inflammatory response on ligand binding and might enhance pro-inflammatory mechanisms in immune/ inflammatory diseases [37] . A previous study showed the sRAGE concentrations were highest in subjects with the G/G genotype, medium in those with the G/S and lowest in S/S genotype carriers [39] . CRP has evolved as an inflammatory risk marker of cardiovascular disease. Hou et al. reported that hypertensive patients had higher serum hs-CRP levels than controls with normal blood levels [55] . The serum CRP was significantly associated with the G82S variant in the Chinese Han population with CAD [41] . Serum CRP concentration has been reported to be in relation to ischemic stroke subtype. CRP levels were significantly higher for all ischemic stroke subtypes compared with controls [56] . In obese subjects, 82S/S carriers showed significantly higher concentrations of AGEs and hs-CRP than G allele carriers, whereas these phenomenon were not observed in non-obese subjects, suggesting the association between 82G/S genetic variant and CRP may be affected by external conditions [54] . AGEs can induce the expression of IL-6 through the RAGE activated pathways in human OA chondrocytes [57] . 82S allele of RAGE genetic variants was reported to related to increased IL-6 and tumor necrosis factor-alpha levels in diabetic patients with CAD [58] . PAI-1 is the major physiological inhibitor for fibrinolysis, which is also implicated in inflammation and tissue remodeling. AGE has the ability to cause platelet aggregation and fibrin stabilization, resulting in a predisposition to thrombogenesis [59] . RAGE is one of the key factors implicated in the up-regulation of PAI-1 in vascular endothelial cells under diabetes-associated metabolic stress [60] . In the present study, we found that the 82S/S homozygote carriers had a lower sRAGE level, higher IL-6, hs-CRP and PAI-1 levels, suggesting a higher inflammatory status in 82S/S carriers compared with the G/S and G/G genotype carriers. We postulate that the 82G/S polymorphism of RAGE gene regulate the aforementioned inflammatory cytokine expressions, causing different inflammation levels in respective carriers thus affects the predisposition of ischemic stroke. Several limitations should be addressed. This is a small-scale case-control study, the conclusion warrants further duplication in larger scale study or, better in different ethnic populations. Secondly, this is a hospital-based study, rather than a population-based study. The enrollment bias may naturally have bias. Finally, we enrolled only Chinese subjects, thus the conclusion may not suit the other ethnic populations.
In conclusion, in the present study, we explored the role of polymorphisms of RAGE gene in determining the susceptibility to ischemic stroke. We found that the presence of 82Ser/ Ser homozygotes had an increased risk for stroke. No significant difference of genotype distributions and alleles frequencies of -429T/C and -374 T/A between stroke and control subjects. The 82S/S was associated with lower sRAGE level and higher IL-6, hs-CRP and PAI-1 levels compared with the other two genotypes. These findings suggest that the 82G/S may be used as a genetic marker for the prediction of stroke occurrence in high risk subjects.
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